Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Council Floats 9.6% Growth Goal for Global Patented Drug Sales by Japan Pharma
Japan’s Growth Strategy Council on March 10 unveiled an outline of a public-private investment roadmap that includes a 9.6% annual growth target for worldwide sales of patented drugs by Japanese pharmaceutical companies, in line with the global average. The roadmap,…
To read the full story
Related Article
- Govt Presents Growth Strategy Draft Ahead of July Approval
July 1, 2026
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Official Hints at Potential Change to Growth Target in Draft Roadmap
June 11, 2026
- LDP Social Security Panel Pushes Greater Reward for Innovation: Honebuto Proposal
June 3, 2026
- MHLW Official Says US MFN Policy Could Be Taken Up by Chuikyo
May 15, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
- LDP Team Urges Patent-Period Price Maintenance, CEA Review in Growth Strategy Proposal
April 27, 2026
- Govt Presents Draft Public-Private Investment Roadmap at Growth Strategy WG
April 27, 2026
- LDP Project Team to Seek Patent-Period Price Maintenance in Growth Strategy Proposal
April 21, 2026
- LDP Pharma Project Team to Compile Roadmap Proposals after Industry Hearings
April 17, 2026
- Pfizer Japan Chief Urges Applying 9.6% Growth Target to Domestic Market
April 7, 2026
- Growth Strategy Council WG Weighs Incentives for Clinical Trial Sites
March 17, 2026
- WG Members Urge Domestic Biologic Production as National Growth Strategy
March 2, 2026
- Executives Urge Stronger CDMO, CRO Base at Drug Discovery WG Meeting
February 27, 2026
- Japan Launches Biotechnology Working Group, Roadmap Draft Due in April
February 4, 2026
- Takeda’s Miyabashira Urges National Strategy Act to Revive Japan as Innovation Powerhouse
January 22, 2026
- Japan Growth Strategy Council to Set Up Drug Discovery Working Group
December 25, 2025
- Growth Strategy Council Seeks Stronger Drug Discovery Infrastructure in Economic Plan
November 11, 2025
- Japan Launches Growth Strategy HQ, Sets Drug Discovery as Priority Field
November 5, 2025
REGULATORY
- US Narrows Scope of Medicare MFN Model, Exempts Orphan-Only Drugs
October 2, 2026
- Japan to Draw Up Growth Strategy Action Plan by Year-End
October 2, 2026
- Chuikyo Backs Broader CEA Price Cuts This Year, Snubs Pharma Plea
October 1, 2026
- Repatha Optimal Use Guidelines to Be Simplified
October 1, 2026
- Label Revisions Ordered for Checkpoint Inhibitors over Gastritis, Esophagitis
September 30, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…